Ricerca avanzata

Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2013 Giugno;55(2) > Panminerva Medica 2013 Giugno;55(2):109-20

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOPANMINERVA MEDICA

Rivista di Medicina Interna

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6

Periodicità: Trimestrale

ISSN 0031-0808

Online ISSN 1827-1898

 

Panminerva Medica 2013 Giugno;55(2):109-20

CUTTING EDGE RESPIRATORY MEDICINE 2013 

An update on idiopathic pulmonary fibrosis

Margaritopoulos G. A., Giannarakis I., Siafakas N. M., Antoniou K. M.

Interstitial Lung Disease Unit, University Hospital of Heraklion, Crete, Greece

Idiopathic pulmonary fibrosis (IPF) is a progressively fibrotic disease with a median survival of 3-5 years. Despite recent advances the pathophysiology of the disease remains not fully understood. However, injury of type II alveolar epithelial cells is considered the key event for the initiation of the development of fibrosis. An accurate diagnosis is imperative because commencing treatment at an early stage may reduce disease progression. In this regard, the multidisciplinary disease meeting between pulmonologists, radiologists and pathologists has definitely improved the diagnostic confidence. Importantly, a milestone has been recently reached as the first IPF-specific drug namely pirfenidone has been licensed in Europe, Japan and Asia.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina